Galena Biopharma Inc
Change company Symbol lookup
Select an option...
GALE Galena Biopharma Inc
CRF Cornerstone Total Return Fund Inc
FNSR Finisar Corp
LECO Lincoln Electric Holdings Inc
BAC Bank of America Corp
ALNY Alnylam Pharmaceuticals Inc
MXCYY Metso Oyj
VITLX Vanguard Institutional Target Retirement 2045 Fund Institutional Shares
NVDA NVIDIA Corp
TTEN Titan Energy LLC
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap GrowthCompany profile

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Closing Price
$0.3503
Day's Change
0.0218 (6.64%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.3503
Day's Low
0.323
Volume
(Light)
Volume:
1,939,629
10-day average volume:
4,158,479
1,939,629
  • Prev Close
    0.3285
  • Today's Open
    0.3283
  • Day's Range
    0.323-0.3503
  • Avg Vol (10-day)
    4.2M
  • Last (time)
    4:00p ET 09/30/16
  • Last (size)
    17
  • 52-Wk Range
    0.275 - 2.49
    LowHigh
  • (06/20/16 - 06/29/16)
    27.38%
  • 200.0%
  • Market Cap
    75.1M
  • Shares Outstanding
    214.5M
  • -0.13
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 2.1
  • 26.78
  • (% of float 09/15/16)
    8.68

Latest News

September 29, 2016
7:05 am ET
Globe Newswire
September 27, 2016
4:05 pm ET
Globe Newswire
September 20, 2016
7:05 am ET
Globe Newswire
September 16, 2016
7:35 am ET
PR Newswire
September 14, 2016
7:05 am ET
Globe Newswire
September 13, 2016
9:50 am ET
Globe Newswire
September 12, 2016
7:05 am ET
Globe Newswire
September 09, 2016
7:05 am ET
Globe Newswire
August 19, 2016
8:34 am ET
Zacks
August 10, 2016
8:32 am ET
MarketWatch
6:42 am ET
Zacks
August 09, 2016
4:07 pm ET
Globe Newswire
July 29, 2016
10:34 am ET
Zacks
July 26, 2016
9:12 am ET
Zacks
7:06 am ET
Globe Newswire
July 20, 2016
7:55 am ET
Zacks
7:40 am ET
PR Newswire
July 13, 2016
4:35 pm ET
Globe Newswire
July 08, 2016
7:35 am ET
Globe Newswire
7:05 am ET
Globe Newswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2016 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by , Computrade Systems, Inc.,, , and

Copyright © 2016. All rights reserved.